Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Receivables: 2012-2019

Historic Change in Receivables for Theravance Biopharma (TBPH) over the last 8 years, with Dec 2019 value amounting to -$620,000.

  • Theravance Biopharma's Change in Receivables rose 96.42% to -$86,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$620,000, marking a year-over-year increase of 62.03%. This contributed to the annual value of -$620,000 for FY2019, which is 62.03% up from last year.
  • Per Theravance Biopharma's latest filing, its Change in Receivables stood at -$620,000 for FY2019, which was up 62.03% from -$1.6 million recorded in FY2018.
  • Theravance Biopharma's Change in Receivables' 5-year high stood at $1.6 million during FY2015, with a 5-year trough of -$1.6 million in FY2018.
  • Its 3-year average for Change in Receivables is -$215,333, with a median of -$620,000 in 2019.
  • In the last 5 years, Theravance Biopharma's Change in Receivables surged by 1,714.44% in 2015 and then slumped by 201.62% in 2018.
  • Over the past 5 years, Theravance Biopharma's Change in Receivables (Yearly) stood at $1.6 million in 2015, then crashed by 178.14% to -$1.3 million in 2016, then skyrocketed by 225.94% to $1.6 million in 2017, then tumbled by 201.62% to -$1.6 million in 2018, then surged by 62.03% to -$620,000 in 2019.